荜茇明目颗粒（BMGG）通过纠正过敏性鼻炎中Th1/Th2和Treg/Th17细胞失衡减轻鼻部炎症

文献信息

中文摘要

过敏性鼻炎（AR）是一种常见的慢性炎症性鼻部疾病，其特征为CD4+ T细胞亚群失衡，尤其是Th1/Th2和Treg/Th17比例紊乱。本研究在体外和体内AR模型中探讨了中药复方荜茇明目颗粒（BMGG）的免疫调节作用。在TNF-α/LPS刺激的HMC-1肥大细胞中，BMGG抑制了异常细胞活力，并调节Th1/Th2相关细胞因子的表达，升高IFN-γ和IL-2水平，同时下调IL-4和IL-5分泌。在卵清蛋白致敏的AR小鼠中，口服BMGG（10、20、40 mg/kg）减轻了鼻部症状、炎症细胞浸润和组织病理学损伤，同时调节IL-17、TGF-β、IL-10和Foxp3以纠正Treg/Th17失衡并恢复全身Th1/Th2稳态。这些发现表明，BMGG通过调节CD4+ T细胞介导的免疫紊乱减轻AR过敏性炎症，支持其作为有效治疗药物的潜力。需要进一步的机制研究和临床试验来验证其安全性和临床价值。

英文摘要

Allergic rhinitis (AR) is a prevalent chronic inflammatory nasal disorder characterised by CD4+ T-cell subset imbalances, particularly disrupted Th1/Th2 and Treg/Th17 ratios. This study investigated the immunomodulatory effects of Bimingan Granule (BMGG), a traditional Chinese medicinal formula, in both in vitro and in vivo AR models. In TNF‑α/LPS‑stimulated HMC‑1 mast cells, BMGG suppressed abnormal cell viability and modulated the expression of Th1/Th2‑associated cytokines, elevating IFN‑γ and IL‑2 levels while downregulating IL‑4 and IL‑5 secretion. In ovalbumin‑sensitized AR mice, oral BMGG (10, 20, 40 mg/kg) alleviated nasal symptoms, inflammatory cell infiltration and histopathological damage, while regulating IL‑17, TGF‑β, IL‑10 and Foxp3 to correct Treg/Th17 imbalance and restore systemic Th1/Th2 homeostasis. These findings demonstrate that BMGG mitigates AR allergic inflammation by modulating CD4+ T cell-mediated immune disorders, supporting its potential as an effective therapeutic agent. Further mechanistic studies and clinical trials are needed to verify its safety and clinical value.